● Recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Condition: Renal Cell Carcinoma · Radiotherapy · Immune Checkpoint Inhibitor · Sponsor: Jinling Hospital, China

PhasePhase 2

Planned participants35

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Le Qu, M. D. · 15720625951 · septsoul@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

Nanjing, Jiangsu, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06255223